Biomarkers in Bone Marrow Samples From Patients With Acute Myeloid Leukemia
Recruitment status was Not yet recruiting
RATIONALE: Studying samples of bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This laboratory study is studying bone marrow samples from patients with acute myeloid leukemia.
Genetic: mutation analysis
Genetic: polymerase chain reaction
Other: immunologic technique
Other: laboratory biomarker analysis
|Official Title:||Somatic Mutations in Stem and Progenitor Cells in AML|
- Define somatic mutations occurring in de novo AML [ Designated as safety issue: No ]
- Selected mutations and order occurrence [ Designated as safety issue: No ]
- Identification of antecedent clonal subpopulations with AML mutations that occur earlier in pathogenesis but not in later pathogenesis [ Designated as safety issue: No ]
|Study Start Date:||September 2010|
|Estimated Primary Completion Date:||October 2010 (Final data collection date for primary outcome measure)|
- To rigorously examine fractionated hematopoietic stem and progenitor cells from patients with acute myeloid leukemia (AML).
- To define somatic mutations occurring in de novo AML, including the FLT3-ITD, CEBPA, NPM1, TET2, ASXL1, IDH1, and IDH2 mutations.
- To examine what cellular compartments (LT-HSC, ST-HSC, CMP, GMP, and MEP) contain the selected mutations and in what order those mutations occur.
OUTLINE: Archived bone marrow specimens are analyzed for sequencing and detection of mutations by Sanger-based resequencing of PCR amplicons. Results are then compared with the results of age-matched healthy controls.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01251159
|Principal Investigator:||Ulrich G. Steidl, MD, BS||Albert Einstein College of Medicine of Yeshiva University|